Prognostic and predictive performance of R-ISS with SKY92 in older patients with multiple myeloma : The HOVON-87/NMSG-18 trial
The standard prognostic marker for multiple myeloma (MM) patients is the revised International Staging System (R-ISS). However, there is room for improvement in guiding treatment. This applies particularly to older patients, in whom the benefit/risk ratio is reduced because of comorbidities and subsequent side effects. We hypothesized that adding gene-expression data to R-ISS would generate a stro